Alcindor, T., Kasper, B., Gounder, M. M., Ratan, R., Van der Graaf, W. T. A., Wilky, B. A., … Schoffski, P. (2023). Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Alcindor, Thierry, Bernd Kasper, Mrinal M. Gounder, Ravin Ratan, Winette T. A. Van der Graaf, Breelyn A. Wilky, Richard F. Riedel, et al. “Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Alcindor T, Kasper B, Gounder MM, Ratan R, Van der Graaf WTA, Wilky BA, et al. Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Alcindor, Thierry, et al. “Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Alcindor T, Kasper B, Gounder MM, Ratan R, Van der Graaf WTA, Wilky BA, Riedel RF, Federman N, Peruzzi A, Moody S, Lim A, Tumminello B, Kummar S, Schoffski P. Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2023.